The Cyclin A2 gene (CCNA2), which turns off after birth in humans, can promote cardiac repair in adult human cardiomyocytes.

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) announced today that it has been accepted to the BioFab Startup Lab, part of the Advanced Regenerative ...

Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories Ltd. ("Alkem"), and Indian Institute of Technology Bombay ("IIT Bombay") today announced a strategic collaboration ...

Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced ...

With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyondCANTON, Mass., Nov. 03, 2025 (GLOBE ...

Pancreas development in pigs resembles humans much more closely than does the established mouse model. An international team ...

The site will feature smart microgrids, solar, and advanced battery storage – a step toward sustainable industrial infrastructure in Florida.

BrainXell Therapeutics today announced the disclosure of its first scientific data, which will be presented at two conferences this month: the Cell Symposia | Gene and Cell-Based Therapies: Progress ...

The human heart has the ability to repair itself, scientists have found, in a breakthrough that could provide a lifeline for ...

Alkem Foundation and IIT Bombay have partnered to establish a research center for immuno-therapeutics and regenerative medicine. The center aims to foster innovation, fill research gaps, and ...

A naturally occurring gene called Cyclin A2 (CCNA2), which turns off after birth in humans, can actually make new, functioning heart cells and help the heart repair itself from injury, including a ...